The importance of maximal airway response to methacholine in the prediction of asthma development in patients with allergic rhinitis

Bisphenol A exposure and asthma development in school-age children: a longitudinal study

BACKGROUND

Although the effect of bisphenol A on various health outcomes has been extensively examined, few studies have investigated its effect on asthma.

OBJECTIVE

We hypothesized that exposure to bisphenol A in school-age children was associated with wheezing and asthma.

METHODS

Participants included 127 children aged 7-8 years without a previous asthma diagnosis in an elementary school in Seoul, Korea. Three surveys were conducted, each 2 years apart. Bisphenol A concentration was measured at the baseline survey, and PC20, which is defined as the methacholine concentration that induces a decrease in FEV1 of 20% from baseline, was measured at every survey. Associations between bisphenol A concentration at 7-8 years of age and wheezing, asthma, and PC20 at ages up to 11-12 years were examined using generalized estimating equations, a marginal Cox regression model, and a linear mixed model.

RESULTS

The log-transformed creatinine-adjusted urinary bisphenol A concentration at 7-8 years was positively associated with wheezing (odds ratio, 2.48; 95% confidence interval, 1.15-5.31; P = .02) and asthma (hazard ratio, 2.13; 95% confidence interval, 1.51-3.00; P<.001) at ages up to 11-12 years. Bisphenol A was also negatively associated with PC20 (ß = -2.33; P = .02). When stratified by sex, the association between bisphenol A and asthma remained significant only in girls (hazard ratio, 2.45; 95% confidence interval, 2.18-2.76; P<.001).

CONCLUSION

Increased urinary bisphenol A concentrations at 7-8 years old were positively associated with wheezing and asthma and negatively associated with PC20 at ages up to 11-12 years.

Clinical implications of airway hyperresponsiveness in COPD

COPD represents one of the leading causes of mortality in the general population. This study aimed at evaluating the relationship between airway hyperresponsiveness (AHR) and COPD and its relevance for clinical practice. We performed a MEDLINE search that yielded a total of 1919 articles. Eligible studies were defined as articles that addressed specific aspects of AHR in COPD, such as prevalence, pathogenesis, or prognosis. AHR appears to be present in at least one out of two individuals with COPD. The occurrence of AHR in COPD is influenced by multiple mechanisms, among which impairment of factors that oppose airway narrowing plays an important role. The main determinants of AHR are reduction in lung function and smoking status. We envision a dual role of AHR: in suspected COPD, specific determinants of AHR, such as reactivity and the plateau response, may help the physician to discriminate COPD from asthma; in definite COPD, AHR may be relevant for the prognosis. Indeed, AHR is an independent predictor of mortality in COPD patients. Smoking cessation has been shown to reduce AHR. Further studies are needed to elucidate whether this functional change is associated with improvement in lung function and respiratory symptoms.

Nonspecific provocation of target organs in allergic diseases: EAACI-GA(2)LEN consensus report

It is widely accepted that nonspecific tissue reactivity is a distinct pathophysiological hallmark of allergic diseases, influenced by genetic and environmental factors different from those involved in causing sensitization and allergen response of target organs. This consensus document aims at reviewing procedures currently used for nonspecific provocation of the bronchi, nose and eye and for measuring their responsiveness to nonspecific stimuli.

Comparison of deltaFVC between patients with allergic rhinitis with airway hypersensitivity and patients with mild asthma

BACKGROUND

In asthmatic individuals, airway sensitivity and maximal airway response are increased. Airway sensitivity is usually evaluated by measuring the provocation concentration of inhaled methacholine or histamine that causes a decrease in forced expiratory volume in 1 second of 20% (PC20). The percentage decrease in forced vital capacity at the PC20 (deltaFVC) has been proposed as a surrogate marker for maximal airway response. Individuals with allergic rhinitis and no clinical evidence of asthma frequently exhibit airway hypersensitivity.

OBJECTIVE

To compare the deltaFVC between patients with allergic rhinitis and mild asthmatic patients with a similar degree of airway hypersensitivity.

METHODS

A retrospective analysis of methacholine challenge test data from 72 children with allergic rhinitis and airway hypersensitivity (methacholine PC20 < 16 mg/mL) (rhinitis group) and from 72 children with mild atopic asthma matched to the rhinitis group regarding the methacholine PC20 (asthma group). The deltaFVC was calculated on the concentration-response curve to methacholine.

RESULTS

The mean +/- SD deltaFVC was significantly lower in the rhinitis group (15.0% +/- 3.6%) vs the asthma group (17.4% +/- 5.3%) (P = .002). There was no significant correlation between the deltaFVC and PC20 in the rhinitis (r = -0.101; P = .41) and asthma (r = -0.023; P = .85) groups when 2 patients with PC20 less than 1 mg/mL were excluded from each group.

CONCLUSIONS

Patients with allergic rhinitis and airway hypersensitivity had a significantly lower deltaFVC than methacholine PC20-matched mild asthmatic patients, suggesting that the level of maximal airway response in patients with allergic rhinitis is lower than that in mild asthmatic patients with a similar degree of airway hypersensitivity.

The development of asthma in patients with allergic rhinitis

PURPOSE OF REVIEW

We will review data supporting the link between allergic rhinitis and asthma, examine recent progress made towards understanding the influence of allergic rhinitis on asthma regarding future development or progression of asthma, and discuss possible mechanisms through which this occurs and potential preventive measures.

RECENT FINDINGS

Several recent reviews have concluded that a close relationship exists between allergic rhinitis and asthma. It has even been proposed that allergic rhinitis and asthma are manifestations of the same disease entity and that they represent a continuum of disease. Allergic rhinitis often precedes the onset of clinical asthma and is a risk factor for the development of asthma. Recognition of this relationship between allergic rhinitis and asthma is highlighted by the recent development of guidelines for the diagnosis and treatment of these disorders by the international Allergic Rhinitis and Its Impact on Asthma workshop. The mechanisms by which allergic rhinitis may be a risk factor for asthma are not entirely understood, although a few recent studies have addressed this question. Some clues in regard to the identification of subjects at risk of developing asthma have been provided by recent studies. Several recent reports support the belief that early introduction of immunotherapy in patients with allergic rhinitis reduces subsequent development of asthma, whereas it remains to be studied whether timely pharmacotherapy for allergic rhinitis may prevent the progression to asthma.

SUMMARY

Because asthma is generally permanent at the time of diagnosis, it would be of great benefit to identify individuals at increased risk of developing asthma in order to provide a window of opportunity in which the progression to asthma could be prevented. As recognition and early treatment of allergic rhinitis could have important consequences in terms of reducing the prevalence and severity of asthma, there is a need to perform further clinical studies that address this issue.